| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 12 | 2023 | 965 | 1.150 |
Why?
|
| Acute Coronary Syndrome | 6 | 2018 | 254 | 1.010 |
Why?
|
| Myocardial Infarction | 11 | 2018 | 921 | 0.990 |
Why?
|
| Wounds and Injuries | 2 | 2025 | 250 | 0.840 |
Why?
|
| Accidental Falls | 1 | 2025 | 130 | 0.800 |
Why?
|
| Platelet Activation | 2 | 2014 | 31 | 0.680 |
Why?
|
| Heart-Assist Devices | 3 | 2020 | 158 | 0.680 |
Why?
|
| Quality Improvement | 3 | 2015 | 468 | 0.610 |
Why?
|
| Emergency Service, Hospital | 5 | 2025 | 1163 | 0.560 |
Why?
|
| Emergency Medicine | 1 | 2020 | 195 | 0.520 |
Why?
|
| Emergency Medical Services | 4 | 2019 | 264 | 0.480 |
Why?
|
| Medical Errors | 2 | 2015 | 202 | 0.470 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 253 | 0.470 |
Why?
|
| Point-of-Care Systems | 2 | 2014 | 137 | 0.450 |
Why?
|
| Patient Safety | 2 | 2015 | 281 | 0.430 |
Why?
|
| Hospitalization | 7 | 2025 | 1403 | 0.410 |
Why?
|
| Photoplethysmography | 4 | 2018 | 38 | 0.400 |
Why?
|
| Ischemic Preconditioning, Myocardial | 4 | 2007 | 23 | 0.370 |
Why?
|
| Cost Savings | 1 | 2013 | 60 | 0.370 |
Why?
|
| Clinical Protocols | 1 | 2013 | 138 | 0.350 |
Why?
|
| Anticoagulants | 3 | 2025 | 529 | 0.340 |
Why?
|
| Male | 31 | 2025 | 31295 | 0.310 |
Why?
|
| Retrospective Studies | 12 | 2025 | 6948 | 0.310 |
Why?
|
| Aged, 80 and over | 13 | 2025 | 5656 | 0.300 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 193 | 0.300 |
Why?
|
| Transportation of Patients | 1 | 2010 | 50 | 0.300 |
Why?
|
| Massachusetts | 14 | 2018 | 2154 | 0.300 |
Why?
|
| Humans | 42 | 2025 | 65650 | 0.300 |
Why?
|
| Myocardial Reperfusion | 2 | 2008 | 23 | 0.290 |
Why?
|
| Hospital Mortality | 8 | 2018 | 879 | 0.290 |
Why?
|
| Female | 30 | 2025 | 34309 | 0.290 |
Why?
|
| Aged | 21 | 2025 | 15089 | 0.290 |
Why?
|
| Myocardium | 3 | 2008 | 302 | 0.290 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 505 | 0.270 |
Why?
|
| Electrocardiography | 5 | 2023 | 555 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2005 | 46 | 0.260 |
Why?
|
| Time Factors | 10 | 2018 | 3777 | 0.260 |
Why?
|
| Atrial Fibrillation | 3 | 2025 | 884 | 0.250 |
Why?
|
| Tachycardia, Ventricular | 2 | 2018 | 131 | 0.240 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 170 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 42 | 0.230 |
Why?
|
| Heart Rate | 3 | 2016 | 334 | 0.230 |
Why?
|
| Ambulatory Care | 2 | 2025 | 318 | 0.230 |
Why?
|
| Middle Aged | 18 | 2025 | 18439 | 0.220 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2005 | 29 | 0.220 |
Why?
|
| Algorithms | 5 | 2019 | 1052 | 0.220 |
Why?
|
| Atrial Flutter | 1 | 2025 | 33 | 0.220 |
Why?
|
| Pharmacists | 2 | 2023 | 131 | 0.210 |
Why?
|
| Acute Disease | 6 | 2015 | 663 | 0.200 |
Why?
|
| Stroke Volume | 2 | 2015 | 345 | 0.190 |
Why?
|
| Support Vector Machine | 2 | 2023 | 25 | 0.190 |
Why?
|
| Inpatients | 2 | 2016 | 322 | 0.180 |
Why?
|
| Myocardial Ischemia | 3 | 2012 | 121 | 0.180 |
Why?
|
| Wearable Electronic Devices | 1 | 2023 | 78 | 0.180 |
Why?
|
| Emergencies | 2 | 2019 | 124 | 0.180 |
Why?
|
| Air Ambulances | 2 | 2014 | 32 | 0.180 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1335 | 0.180 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2018 | 33 | 0.170 |
Why?
|
| Intensive Care Units | 1 | 2025 | 436 | 0.170 |
Why?
|
| Prognosis | 9 | 2018 | 1791 | 0.170 |
Why?
|
| Communication | 2 | 2018 | 606 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 409 | 0.160 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2018 | 96 | 0.160 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 30 | 0.150 |
Why?
|
| Emergency Treatment | 1 | 2019 | 55 | 0.150 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2016 | 99 | 0.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2015 | 139 | 0.140 |
Why?
|
| Patient Discharge | 4 | 2020 | 521 | 0.140 |
Why?
|
| Hypovolemia | 1 | 2018 | 17 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 175 | 0.140 |
Why?
|
| Information Seeking Behavior | 1 | 2018 | 39 | 0.140 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 9 | 0.140 |
Why?
|
| Blood Volume | 1 | 2018 | 40 | 0.130 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 154 | 0.130 |
Why?
|
| Hyperglycemia | 1 | 2018 | 109 | 0.130 |
Why?
|
| Ventricular Fibrillation | 1 | 2018 | 108 | 0.130 |
Why?
|
| Artifacts | 2 | 2016 | 128 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 162 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2025 | 1662 | 0.130 |
Why?
|
| Patient Admission | 1 | 2018 | 200 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 201 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2015 | 152 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2018 | 286 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 489 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2018 | 284 | 0.120 |
Why?
|
| Pulse | 1 | 2015 | 16 | 0.120 |
Why?
|
| Atrial Premature Complexes | 1 | 2015 | 12 | 0.120 |
Why?
|
| Radio Frequency Identification Device | 1 | 2015 | 10 | 0.120 |
Why?
|
| Telemetry | 1 | 2015 | 17 | 0.120 |
Why?
|
| Ventricular Premature Complexes | 1 | 2015 | 20 | 0.120 |
Why?
|
| Electronic Health Records | 2 | 2023 | 398 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2015 | 3329 | 0.110 |
Why?
|
| Smartphone | 1 | 2015 | 75 | 0.110 |
Why?
|
| Internet | 1 | 2018 | 472 | 0.110 |
Why?
|
| Peer Review, Health Care | 1 | 2014 | 16 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2014 | 52 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2015 | 202 | 0.100 |
Why?
|
| Survival Rate | 5 | 2015 | 847 | 0.100 |
Why?
|
| Lactates | 1 | 2014 | 28 | 0.100 |
Why?
|
| Executive Function | 1 | 2014 | 68 | 0.100 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 126 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 63 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 78 | 0.100 |
Why?
|
| Mobile Applications | 1 | 2015 | 142 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 137 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2014 | 106 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 169 | 0.100 |
Why?
|
| Risk Factors | 7 | 2018 | 5466 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2014 | 224 | 0.090 |
Why?
|
| Adult | 8 | 2025 | 17511 | 0.090 |
Why?
|
| Troponin I | 1 | 2012 | 36 | 0.090 |
Why?
|
| Rabbits | 4 | 2005 | 342 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 214 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 235 | 0.090 |
Why?
|
| Ambulances | 1 | 2012 | 25 | 0.090 |
Why?
|
| Protein Subunits | 1 | 2012 | 169 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 133 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2016 | 452 | 0.090 |
Why?
|
| Transcription Factor AP-1 | 2 | 2001 | 46 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2015 | 888 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2014 | 593 | 0.090 |
Why?
|
| Biomarkers | 3 | 2018 | 1487 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 169 | 0.090 |
Why?
|
| Mortality | 1 | 2012 | 162 | 0.080 |
Why?
|
| Creatine Kinase | 2 | 2010 | 42 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2014 | 2639 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 35 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 46 | 0.080 |
Why?
|
| Critical Illness | 1 | 2014 | 340 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 23 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2014 | 1026 | 0.080 |
Why?
|
| Organizational Policy | 1 | 2010 | 50 | 0.080 |
Why?
|
| Medical Audit | 1 | 2010 | 67 | 0.080 |
Why?
|
| Incidence | 3 | 2018 | 1432 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 1172 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 555 | 0.070 |
Why?
|
| Platelet Function Tests | 1 | 2008 | 11 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 707 | 0.070 |
Why?
|
| Heart Conduction System | 1 | 2007 | 50 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 235 | 0.060 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2005 | 27 | 0.060 |
Why?
|
| Gap Junctions | 1 | 2005 | 18 | 0.060 |
Why?
|
| Comorbidity | 3 | 2015 | 1120 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2005 | 109 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 178 | 0.050 |
Why?
|
| Warfarin | 1 | 2025 | 125 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2025 | 288 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 1 | 2005 | 96 | 0.050 |
Why?
|
| Disease Progression | 2 | 2019 | 1227 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 151 | 0.050 |
Why?
|
| Narcotics | 1 | 2004 | 57 | 0.050 |
Why?
|
| Apnea | 1 | 2004 | 33 | 0.050 |
Why?
|
| Age Factors | 3 | 2014 | 1592 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 2496 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1144 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2001 | 344 | 0.050 |
Why?
|
| Jejunum | 1 | 2002 | 15 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2002 | 15 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2023 | 371 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 1273 | 0.050 |
Why?
|
| Medication Errors | 1 | 2023 | 127 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2002 | 55 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 775 | 0.040 |
Why?
|
| United States | 3 | 2025 | 8166 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1116 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2016 | 757 | 0.040 |
Why?
|
| Prevalence | 2 | 2016 | 1453 | 0.040 |
Why?
|
| Hypotonic Solutions | 1 | 2000 | 7 | 0.040 |
Why?
|
| Ischemia | 1 | 2002 | 203 | 0.040 |
Why?
|
| Actins | 1 | 2001 | 265 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2001 | 175 | 0.040 |
Why?
|
| Animals | 7 | 2008 | 21467 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2015 | 5820 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 87 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2019 | 55 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 213 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 105 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 308 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 128 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 931 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2019 | 222 | 0.030 |
Why?
|
| Georgia | 1 | 2018 | 92 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 177 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2730 | 0.030 |
Why?
|
| Consumer Health Information | 1 | 2018 | 41 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2014 | 900 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2012 | 225 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 2019 | 180 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2012 | 611 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2018 | 296 | 0.030 |
Why?
|
| Attitude to Computers | 1 | 2015 | 17 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2018 | 502 | 0.030 |
Why?
|
| Gelatin | 1 | 2015 | 31 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 2015 | 54 | 0.030 |
Why?
|
| Movement | 1 | 2016 | 166 | 0.030 |
Why?
|
| Liver | 1 | 2000 | 874 | 0.030 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2014 | 13 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 429 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 79 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 157 | 0.030 |
Why?
|
| Oximetry | 1 | 2014 | 53 | 0.030 |
Why?
|
| Motion | 1 | 2014 | 66 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 390 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 178 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2014 | 27 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 143 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 162 | 0.020 |
Why?
|
| Cause of Death | 1 | 2014 | 221 | 0.020 |
Why?
|
| Naloxone | 2 | 2004 | 53 | 0.020 |
Why?
|
| Aspirin | 1 | 2014 | 172 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 992 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 414 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 442 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2014 | 292 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 68 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 95 | 0.020 |
Why?
|
| Narcotic Antagonists | 2 | 2004 | 133 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 201 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 328 | 0.020 |
Why?
|
| Osmotic Pressure | 2 | 2001 | 17 | 0.020 |
Why?
|
| Heart | 2 | 2004 | 298 | 0.020 |
Why?
|
| Depression | 1 | 2018 | 908 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2013 | 230 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2113 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2001 | 3164 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 491 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 348 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 579 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1715 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 426 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2001 | 128 | 0.020 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 226 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 828 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2001 | 216 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 23 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 995 | 0.020 |
Why?
|
| Diuretics | 1 | 2009 | 58 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2010 | 157 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2009 | 107 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2001 | 963 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1288 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 463 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 200 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2789 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2008 | 124 | 0.020 |
Why?
|
| Life Style | 1 | 2009 | 324 | 0.020 |
Why?
|
| Rats | 2 | 2001 | 2002 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 376 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2008 | 267 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 4855 | 0.010 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2005 | 42 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 1235 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1567 | 0.010 |
Why?
|
| Glyburide | 1 | 2002 | 9 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 2002 | 11 | 0.010 |
Why?
|
| Potassium Channel Blockers | 1 | 2002 | 23 | 0.010 |
Why?
|
| Mesentery | 1 | 2002 | 17 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2001 | 12 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2001 | 18 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2001 | 14 | 0.010 |
Why?
|
| Chromones | 1 | 2001 | 18 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2001 | 17 | 0.010 |
Why?
|
| Second Messenger Systems | 1 | 2001 | 27 | 0.010 |
Why?
|
| Culture Media | 1 | 2001 | 78 | 0.010 |
Why?
|
| Morpholines | 1 | 2001 | 91 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2001 | 141 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2002 | 209 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 3501 | 0.010 |
Why?
|
| Kidney | 1 | 2003 | 458 | 0.010 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2000 | 17 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 451 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2000 | 86 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 149 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 371 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2001 | 604 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2000 | 626 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2000 | 435 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2001 | 634 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 1625 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 11174 | 0.010 |
Why?
|